Invest now in Preclinical Phase

The demonstration of true clinical proof-of-concept is a key value-creation step in the clinical development of a medicine.

Invest in the future. Invest in life science. We are looking for next 15 months seed capital to financing & reach till Clinical Phase I

500 000 €

Cover investment needs to reach and design the pre-clinical phase where the result of the solution discovered will be final confirmed, and prepare development of the first phase of the Melasma for early stage of Phase I. Included: Process management / R&D project with Micar Innovation / Research and Development Process / Building the management & operational teams for growth.

Our Roadmap

The demonstration of true clinical proof-of-concept is a key value-creation step in the clinical development of a medicine.

The business model

The business model is based on discovering drugs and developing drug until phase 2a “Proof of concept" (PoC) and licensing them to the best possible commercial partner.

We are open

Melasma Pharmaceuticals are always open for Licensing deals / M&A / Strategic Collaboration / Development Veterinary drug – companion animals (Licensing deals)

Partnerships

Melasma Pharmaceuticals searching strategic Partnerships / Collaborations with other Biotech / Big Pharma / CRO in Dermatology therapeutic area.

Investment

We searching strategic investment with other Biotech / Venture Capital / Angel Investors

Please see Pitch desk in PDF

Invest now in Preclinical Phase - Melasma Pharmaceuticals

Melasma Pharmaceuticals is transforming the treatment of melasma. We aim to bridge the safety and efficacy gaps in current approaches to melasma management.

Our Mission

Melasma is a growing problem – not only in terms of the significant number of people that are impacted and the burden this places on our healthcare system. Our mission is to relieve the suffering associated with melasma by developing treatments that address the safety and efficacy gaps in the current treatment paradigm.

Our broad pipeline represents our mission to tackle the problem of melasma head on by developing treatments that act at new or emerging pharmacological targets and delivering them in ways that best address the particular type of melasma.